45.02
price down icon1.60%   -0.73
after-market Handel nachbörslich: 45.02
loading
Schlusskurs vom Vortag:
$45.75
Offen:
$45.78
24-Stunden-Volumen:
706.34K
Relative Volume:
0.92
Marktkapitalisierung:
$2.60B
Einnahmen:
$1.28B
Nettoeinkommen (Verlust:
$-222.15M
KGV:
-11.01
EPS:
-4.09
Netto-Cashflow:
$145.52M
1W Leistung:
-1.21%
1M Leistung:
+4.09%
6M Leistung:
-1.49%
1J Leistung:
-17.88%
1-Tages-Spanne:
Value
$44.28
$46.17
1-Wochen-Bereich:
Value
$44.28
$46.92
52-Wochen-Spanne:
Value
$32.48
$57.35

Livanova Plc Stock (LIVN) Company Profile

Name
Firmenname
Livanova Plc
Name
Telefon
4402033250662
Name
Adresse
20 EASTBOURNE TERRACE, LONDON
Name
Mitarbeiter
2,900
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
LIVN's Discussions on Twitter

Vergleichen Sie LIVN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Medical Devices icon
LIVN
Livanova Plc
45.02 2.60B 1.28B -222.15M 145.52M -4.09
Medical Devices icon
ABT
Abbott Laboratories
136.01 233.36B 42.34B 13.50B 6.66B 7.71
Medical Devices icon
BSX
Boston Scientific Corp
107.41 147.06B 17.55B 2.03B 2.72B 1.37
Medical Devices icon
SYK
Stryker Corp
395.63 145.64B 23.22B 2.86B 3.58B 7.40
Medical Devices icon
MDT
Medtronic Plc
87.17 112.76B 33.54B 4.66B 5.19B 3.62
Medical Devices icon
EW
Edwards Lifesciences Corp
78.21 44.46B 5.54B 4.18B 623.10M 7.00

Livanova Plc Stock (LIVN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-20 Hochstufung Wolfe Research Peer Perform → Outperform
2025-02-26 Herabstufung Wolfe Research Outperform → Peer Perform
2024-10-04 Eingeleitet Goldman Buy
2024-09-17 Hochstufung Robert W. Baird Neutral → Outperform
2024-03-20 Bestätigt Needham Buy
2024-02-20 Hochstufung Mizuho Neutral → Buy
2023-09-06 Eingeleitet HSBC Securities Hold
2023-07-19 Eingeleitet Robert W. Baird Neutral
2023-04-14 Eingeleitet Mizuho Neutral
2022-12-21 Eingeleitet Barclays Equal Weight
2022-04-06 Eingeleitet Wolfe Research Outperform
2022-02-24 Hochstufung UBS Neutral → Buy
2021-12-03 Eingeleitet Goldman Buy
2021-08-20 Bestätigt Needham Buy
2021-07-20 Hochstufung Needham Hold → Buy
2021-03-03 Herabstufung Berenberg Buy → Hold
2021-01-05 Herabstufung Needham Buy → Hold
2020-09-02 Eingeleitet Robert W. Baird Outperform
2020-06-26 Bestätigt Needham Buy
2019-10-30 Bestätigt Needham Buy
2019-02-28 Bestätigt Needham Buy
2018-11-28 Eingeleitet UBS Neutral
2018-08-02 Bestätigt Needham Buy
2018-06-08 Eingeleitet Stifel Buy
2018-05-31 Bestätigt Needham Buy
2018-02-28 Bestätigt Needham Buy
Alle ansehen

Livanova Plc Aktie (LIVN) Neueste Nachrichten

pulisher
Jun 16, 2025

Global Neurostimulation Devices Market to grow at a CAGR - openPR.com

Jun 16, 2025
pulisher
Jun 15, 2025

(LIVN) Investment Report - news.stocktradersdaily.com

Jun 15, 2025
pulisher
Jun 14, 2025

LivaNova’s SWOT analysis: medical device firm’s stock faces growth hurdles By Investing.com - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 13, 2025

Wearable Cardioverter Defibrillators (WCD) Market Growth | - openPR.com

Jun 13, 2025
pulisher
Jun 11, 2025

LivaNova Shareholders Approve New Incentive Plans - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

LivaNova Shareholders Approve New Incentive Plans By Investing.com - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

LivaNova Shareholders Approve Key Incentive Plans at AGM - TipRanks

Jun 11, 2025
pulisher
Jun 10, 2025

Livanova petitions CMS to drop CED mandate for VNS for depression - BioWorld MedTech

Jun 10, 2025
pulisher
Jun 06, 2025

LivaNova completes epilepsy treatment study of VNS Therapy - Medical Device Network

Jun 06, 2025
pulisher
Jun 05, 2025

LivaNova reports positive VNS Therapy study results for epilepsy By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

VNS therapy shows sustained seizure reduction in study By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy - BioSpace

Jun 05, 2025
pulisher
Jun 05, 2025

LivaNova at Jefferies Conference: Strategic Growth and Challenges By Investing.com - Investing.com India

Jun 05, 2025
pulisher
Jun 05, 2025

LivaNova at Jefferies Conference: Strategic Growth and Challenges - Investing.com

Jun 05, 2025
pulisher
Jun 05, 2025

Artificial Heart Lung Machines Market Projected to Witness - openPR.com

Jun 05, 2025
pulisher
Jun 05, 2025

LIVN Reports Promising Outcomes in Drug-Resistant Epilepsy Study - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

LIVN Reports Promising Outcomes in Drug-Resistant Epilepsy Study | LIVN Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

LivaNova reports positive VNS Therapy study results for epilepsy - Investing.com

Jun 05, 2025
pulisher
Jun 05, 2025

CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy | LIVN Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Th - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy | LIVN Stock - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

LivaNova plc (LIVN) completes CORE-VNS study - StreetInsider

Jun 05, 2025
pulisher
Jun 05, 2025

VNS therapy shows sustained seizure reduction in study - Investing.com

Jun 05, 2025
pulisher
Jun 05, 2025

CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy - Business Wire

Jun 05, 2025
pulisher
Jun 05, 2025

LivaNova (LIVN) Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy - StreetInsider

Jun 05, 2025
pulisher
Jun 04, 2025

LivaNova seeks Medicare coverage reconsideration for VNS Therapy By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

LivaNova wants CMS to reconsider neuromod for treating depression - MassDevice

Jun 04, 2025
pulisher
Jun 04, 2025

Bioelectronic Medicine Market Research Report 2025 Featuring Key PlayersMedtronic, Abbott, Boston Scientific, Cochlear, LivaNova, Soterix Medical, Bioinduction, GiMer Medical, CEFALY, BioControl - GlobeNewswire

Jun 04, 2025
pulisher
Jun 04, 2025

LivaNova Seeks Reconsideration of National Medicare Coverage for VNS Depression Treatment - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

LivaNova Initiates Process with U.S. Centers for Medicare and Me - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

LivaNova (LIVN) Seeks Expanded Medicare Coverage for VNS Therapy - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

LivaNova seeks Medicare coverage reconsideration for VNS Therapy - Investing.com India

Jun 04, 2025
pulisher
Jun 04, 2025

LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression | LIVN Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

LivaNova (LIVN) Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression - StreetInsider

Jun 04, 2025
pulisher
May 29, 2025

LivaNova Announces 12-month Data from OSPREY Study - Medical Product Outsourcing

May 29, 2025
pulisher
May 28, 2025

Vagus Nerve Stimulation (VNS) Market Poised for Breakthrough Growth: From $488.5M in 2022 to $836.1M by 2032 - openPR.com

May 28, 2025
pulisher
May 27, 2025

LivaNova PLC (NASDAQ:LIVN) Receives Average Recommendation of “Buy” from Analysts - Defense World

May 27, 2025
pulisher
May 26, 2025

Electroceuticals Market Generated Opportunities, Future - openPR.com

May 26, 2025
pulisher
May 26, 2025

LivaNova’s SWOT analysis: medical device firm’s stock faces growth hurdles - Investing.com Australia

May 26, 2025
pulisher
May 25, 2025

LivaNova's SWOT analysis: medical device firm's stock faces growth hurdles - Investing.com

May 25, 2025
pulisher
May 23, 2025

(LIVN) Technical Data - news.stocktradersdaily.com

May 23, 2025
pulisher
May 23, 2025

LivaNova PLC (NASDAQ:LIVN) Shares Acquired by Deutsche Bank AG - Defense World

May 23, 2025
pulisher
May 22, 2025

LivaNova faces $360M liability after court ruling By Investing.com - Investing.com South Africa

May 22, 2025
pulisher
May 22, 2025

LivaNova (NASDAQ:LIVN) Raised to Outperform at Wolfe Research - Defense World

May 22, 2025
pulisher
May 21, 2025

LivaNova faces $360M liability after court ruling - Investing.com Australia

May 21, 2025

Finanzdaten der Livanova Plc-Aktie (LIVN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Livanova Plc-Aktie (LIVN) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Bianchi Francesco
Director
Jun 15 '25
Option Exercise
0.00
3,416
0
10,938
SCHERMERHORN TODD C
Director
Jun 15 '25
Option Exercise
0.00
3,416
0
9,473
KOZY WILLIAM A
Director
Jun 15 '25
Option Exercise
0.00
4,840
0
33,148
Barry James Christopher
Director
Jun 15 '25
Option Exercise
0.00
3,416
0
4,772
Story Brooke
Director
Jun 15 '25
Option Exercise
0.00
3,416
0
6,892
Enxing Seng Stacy
Director
Jun 15 '25
Option Exercise
0.00
3,416
0
12,161
WILVER PETER M
Director
Jun 15 '25
Option Exercise
0.00
3,416
0
7,148
Tezel Ahmet
Chief Innovation Officer
Jun 15 '25
Option Exercise
0.00
2,967
0
2,967
Bolton Stephanie
President, Global Epilepsy
Mar 30 '25
Option Exercise
0.00
6,024
0
15,586
Makatsaria Vladimir
Chief Executive Officer
Mar 30 '25
Option Exercise
0.00
9,330
0
9,330
$314.18
price up icon 0.35%
medical_devices PHG
$23.98
price down icon 0.66%
medical_devices STE
$240.22
price up icon 0.60%
$87.29
price up icon 1.11%
$74.07
price down icon 0.42%
medical_devices EW
$78.21
price up icon 0.00%
Kapitalisierung:     |  Volumen (24h):